LGC and Genolution partner to accelerate high-throughput nucleic acid purification for agrigenomics

London, UK – 11 September 2025 – Biosearch Technologies, a part of LGC’s Diagnostics and Genomics division and a global leader in life sciences, has signed a Memorandum of Understanding (MoU) with Genolution, a leading Korean-based molecular diagnostics and automation company, to enable LGC’s sbeadexTM Lightning nucleic acid purification chemistry on Genolution’s Nextractor® NX-Duo (NX-Duo) automated platform across Asia Pacific, Europe, Middle East, Canada, and Latin America.

The collaboration combines LGC’s sbeadex Lightning magnetic bead-based chemistry with the NX-Duo’s automated design to deliver a robust, flexible and scalable solution for high-efficiency nucleic acid purification. The partnership will support agrigenomic laboratories and molecular breeders seeking to improve efficiency, increase throughput, and obtain high-quality DNA across diverse sample types.

“By combining LGC’s innovative sbeadex Lightning technology with Genolution’s user-friendly automation, we’ve created a fast and intuitive system that streamlines nucleic acid purification,” said Thomas Winkelmueller, Product Manager, LGC Diagnostics & Genomics. “Our goal is to help customers accelerate plant research and molecular breeding workflows, delivering the highest quality DNA in a fraction of the time.”

“Partnering with LGC expands the performance and versatility of the NX-Duo platform,” said Minlee Kim, Ph.D. CTO, Genolution. “Together, we’re delivering a fit-for-purpose solution to meet growing demand in agrigenomics.”

The NX-Duo platform, known for its flexible throughput ease of use, will be fully adapted to support sbeadex Lightning chemistry in a ready-to-use fully kitted solution. Customers will benefit from faster processing times, pre-filled plates that reduce hands-on time, and improved reproducibility, without compromising on DNA quality.

LGC and Genolution share commitment to provide reliable, scalable, and quality tools to the global agricultural genomics research sector. Field evaluation and commercialisation activities by Genolution commenced in the second half of 2025.

About LGC

LGC is a global leader in life sciences, diagnostics, and analytical solutions. The company partners with customers to solve some of the world’s most pressing challenges. Every day, its science helps to diagnose disease, treat illness, feed a growing population, and protect public health.

LGC provides the components, standards, and services that underpin scientific discovery, enables better health outcomes, and safeguards the integrity of food, water, medicines, and the environment.

With operations in 14 countries and a heritage of over 180 years, LGC’s products and services are integral to public health and global sustainability. From supporting the accuracy of medical test results to verifying the safety of baby food, to helping scientists develop the next generation of medicines, LGC’s solutions are trusted by customers in more than 170 countries.

About Genolution

Established in 2006, Genolution Inc. has been providing solutions toward a better life by focusing on the fields of molecular diagnostics and RNAi. Our core technologies to develop faster, more affordable, and higher through-put nucleic acid extraction platforms led to the development of the Nextractor nucleic acid extraction instrument series and extraction kits; they were vital for our progress in the fields of molecular diagnostics, genetic testing, and life sciences research. Moreover, our double-stranded RNA (dsRNA) synthesis technology enabled us to equip researchers with large-scale dsRNA for gene expression studies and pest control product development.

Our endeavors to provide better quality and better solutions in the fields of IVD and RNAi have led to numerous partners in academia, government institutes, reference labs, as well as industry leaders around the globe.

As a publicly listed company in KOSDAQ as of July 2020, Genolution aims for utmost accountability and transparency. We will make every effort to manifest our dreams and become a Global Life Sciences Group.

CONTACTS

LGC

Business contact:

Thomas Winkelmüller, Product Manager Thomas.Winkelmueller@LGCGroup.com

+ 4915221502270

Media contact:

Magda Bartoszewicz, Director, Corporate Brand and Communications magda.barto@lgcgroup.com

+44 (0) 7408 850 514

Genolution: Lee Dae Sup, IR Team manager ds.lee@genolution1.com

T 070-4104-0886, C +82 10-9020-9323